Estrogen enhances mechanical stress-induced prostaglandin production by bone cells from elderly women. Am J Physiol Endocrinol Metab 280: E436-E442, 2001.-Several studies indicate that estrogen may enhance the effects of mechanical loading on bone mineral density in elderly women. This stimulating effect of estrogen could be due to increased sensitivity of bone cells to mechanical stress in the presence of estrogen. The present study was performed to determine whether 17␤-estradiol (E 2 ) enhances mechanical stress-induced prostaglandin production and cyclooxygenase (COX)-2 mRNA expression. We subjected bone cells from seven nonosteoporotic women between 56 and 75 yr of age for 1 h to pulsating fluid flow (PFF) in the presence or absence of 10 Ϫ11 M E 2 and measured prostaglandin production and COX-1 and COX-2 mRNA expression. One hour of PFF stimulated prostaglandin (PG)E 2 production threefold, PGI 2 production twofold, and COX-2, but not COX-1, mRNA expression 2.9-fold. Addition of E 2 further enhanced PFF-stimulated PGE 2 production by 1.9-fold but did not significantly affect PGI 2 production or COX-2 or COX-1 mRNA expression. E 2 by itself did not affect any of the parameters measured. These results suggest that estrogen modulates bone cell mechanosensitivity via the prostaglandin synthetic pathway independently of COX mRNA expression.
MECHANICAL LOADING OF BONE is an important regulator of bone structure and bone mass. Several animal studies have demonstrated the anabolic effect of additional loading (2, 3) and the bone resorbing effect of unloading of bone (20, 30) .
Although the anabolic effect of additional loading is well known, the nature of the mechanical signal is still not completely characterized. Several studies suggest that osteocytes are the professional stress-sensing cells of bone and that flow of interstitial fluid in the lacunocanalicular network, caused by loading-derived bone strain, provides the mechanical signal for osteocyte mechanosensing (15, 16, 29) . We showed earlier that bone cells in vitro respond to fluid flow of ϳ1 Pa, calculated to be of physiological magnitude (31) , with the rapid production of prostaglandins and nitric oxide (13, 15, 28) .
Several studies have shown that prostaglandins are involved in the signaling pathway leading to adaptive bone formation (4, 9) . Prostaglandins are produced by osteoblastic cells and are abundant in bone (8, 21) . Moreover, bone cells respond to mechanical stress with an increase in prostaglandin production, and osteocytes have been shown to be even more sensitive than osteoblasts (1, 15, 32) . Prostaglandins are generated by phospholipase A 2 -mediated release of arachidonic acid from phospholipids in the cell membrane, followed by conversion of arachidonic acid into prostaglandin (PG)G 2 and subsequently into PGH 2 . PGH 2 is then isomerized to the biologically active prostanoids, including PGE 2 , PGI 2 , and PGF 2␣ . The enzyme prostaglandin G/H synthase, or cyclooxygenase (COX), is involved in the rate-limiting conversion of PGG 2 into PGH 2 (26) . COX mRNA levels, enzyme synthesis, and enzyme activity are upregulated in various cell types by several factors, including growth factors, inflammatory mediators, and hormones (7) . COX is present in two isoforms: a constitutive form (COX-1) and an inducible form (COX-2). Although COX-1 is constitutively expressed in several cell types, including endothelial and murine calvarial cells, it can be modulated by serum factors (11, 18) . COX-2 is not constitutively present in most tissues, but COX-2 mRNA expression can be induced rapidly and transiently among other factors by serum factors (22, 23) . We showed earlier that primary human bone cells respond to pulsating fluid flow (PFF) with an increase in COX-2, but not COX-1, mRNA expression (13) . Interestingly, an animal study by Forwood (9) had demonstrated the crucial role of COX-2 in loading-adaptive osteogenic responses of rat bone in vivo. Therefore, the in vitro induction of COX-2 by fluid flow seems to mimic an early event in loading-adaptive bone formation.
Although mechanical stress acts locally, estrogen, as a systemic hormone, may generally enhance the effect of local loading (3, 12, 17) and abolish the effect of unloading (33) . It is still unclear at what level estrogen interacts with the signaling pathway leading to functional adaptation. It has been suggested that estrogen influences comparative late processes in the mechanoadaptive response of bone tissue (12) . On the other hand, it cannot be excluded that estrogen also modulates the strain-sensing bone cells themselves or their mechanically induced responses (24) .
In this study, we investigated whether estrogen modulation of adaptive bone formation occurs also at the level of cell mechanosensing. Therefore, we studied the effect of 17␤-estradiol on fluid flow-stimulated prostaglandin production and COX-1 and COX-2 mRNA expression by human bone cells in vitro.
MATERIALS AND METHODS

Donors.
Transiliac bone biopsies were obtained from seven postmenopausal women (age 56-75 yr) who were not osteoporotic, were without other metabolic bone disease, and had entered the hospital for orthopedic surgery (elective joint replacement). The Ethics Board of the Academic Hospital Vrije Universiteit approved the protocol, and all subjects gave informed consent.
Culture of primary human bone cells. Cell cultures were established as described earlier (28) . Briefly, the biopsies were placed in sterile PBS at 4°C and were dissected within 1 h after removal. They were chopped into small fragments, washed extensively and repeatedly with PBS, and incubated with 2 mg/ml of collagenase IA (Sigma, St. Louis, MO) for 2 h at 37°C in a shaking waterbath to remove all soft tissue from the bone chip's surface. After collagenase treatment, the denuded bone fragments were washed once with medium containing 10% fetal bovine serum (FBS; GIBCO, Paisley, UK) to inhibit further collagenase activity and then transferred to 25-cm 2 flasks (Nunc, Roskilde, Denmark). They were cultured in DMEM (GIBCO) supplemented with 100 U/ml of penicillin (Sigma), 50 g/ml of streptomycin sulfate (Sigma), 50 g/ml of gentamycin (GIBCO), 1.25 g/ml of fungizone (GIBCO), 100 g/ml of ascorbate (Merck, Darmstadt, Germany), and 10% FBS. Culture medium was replaced 3 times/wk. When the cell monolayer growing from the bone fragments reached confluency, cells were trypsinized, plated at 25 ϫ 10 3 cells/well in 6-well culture dishes (Costar, Cambridge, MA), and cultured in medium as described above.
Cell characterization: 1,25-dihydroxyvitamin D 3 challenge, expression of von Willebrand factor. To test their osteoblastic phenotype, bone-derived cell cultures were incubated for 2 days in the presence or absence of 10 Ϫ8 M 1,25-dihydroxyvitamin D 3 in medium supplemented with 0.2% BSA. Osteocalcin was measured in the conditioned medium by radioimmunoassay (Incstar, Stillwater, MN) by use of an antibody raised against bovine osteocalcin. The detection limit was 0.2 ng/ml. All osteocalcin values were corrected for the amount of osteocalcin in medium with 0.2% BSA (Sigma) and for the total amount of protein present in the cell layer. Alkaline phosphatase activity was determined in the cell lysate by use of p-nitrophenyl phosphate (Merck) as a substrate at pH 10.3, according to the method described by Lowry (19) . The assay was performed in 96-well microtiter plates, and the absorbance was read at 410 nm by a Dynatech MR7000 microplate reader (Dynatech, Billinghurst, UK). To test the presence of endothelial cells in the bone cell cultures, cells were stained for expression of the endothelial cell-specific factor VIII, von Willebrand factor (vWF), by immunofluorescence with the use of a monoclonal vWF antibody. Cultures of primary human umbilical cord-derived endothelial cells served as positive control for the human bone cell cultures.
PFF. Two days before PFF treatment, the culture medium was replaced by DMEM without phenol red (GIBCO) containing 10 Ϫ11 M 17␤-estradiol (E 2 ) or vehicle and supplemented with 0.2% BSA to avoid serum stimulation of COX mRNA expression (14) . Antibiotics and ascorbate were added as usual. Similar medium, with or without E 2 , was used during PFF experiments. PFF (5 Hz) was generated by pumping 12 ml of culture medium by means of a roller pump through a parallel-plate flow chamber containing the bone cells as described previously (15) . The fluid shear stress was 0.6 Ϯ 0.3 Pa, and the estimated peak stress rate was 8.4 Pa/s. Control cultures were kept under stationary conditions in a petri dish, containing the same amount of medium as in the PFF apparatus, at 37°C in a humidified atmosphere of 5% CO 2 in air. Stationary and PFF-treated cultures, either in the presence or absence of E 2 , were studied simultaneously. After 1 h of fluid flow treatment, the conditioned medium was collected and assayed for PGE 2 , PGI 2 , and PGF 2␣ production. The cells were harvested to isolate total DNA and RNA, as described in Total RNA, DNA, and protein.
PGE 2 . PGE 2 release in the conditioned medium was measured by an enzyme immunoassay (EIA) system (Amersham, Buckinghamshire, UK) with the use of an antibody raised against mouse PGE 2 . The detection limit was 16 pg/ml. Absorbance at 450 nm was determined with the Dynatech MR7000 microplate reader. PGI 2 . Because PGI 2 rapidly and spontaneously hydrolyzes to its stable metabolite 6-keto-PGF 1␣ , this metabolite was measured by an EIA system with the use of an antibody raised against rabbit 6-keto-PGF 1␣ . The detection limit was 3.0 pg/ml. Absorbance at 450 nm was determined with the Dynatech MR7000 microplate reader.
PGF 2␣ . PGF2␣ release in the conditioned medium was measured by a 3 H assay system (Amersham) using a PGF 2␣ -specific antibody. The detection limit was 30 pg/ml. Radioactivity was measured in a ␤-scintillation counter (EG and G Wallac, Turku, Finland).
Total RNA, DNA, and protein. RNA, DNA, and protein were isolated from the bone cells by means of TRIzol reagent (GIBCO) according to the manufacturer's instructions. The amount of protein was determined with a bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL). Absorbance at 570 nm was determined with the Dynatech MR7000 microplate reader. The RNA and DNA content was determined by measurement of absorbance at 260 nm with an Ultrospec III spectrophotometer (Amersham).
cDNA synthesis and RT-PCR. cDNA synthesis was performed with 1 g of total RNA. After incubation of the RNA at 65°C for 2 min, cDNA synthesis was performed with the following final reaction concentrations: 500 M dNTPs (GIBCO), 10 units RNase inhibitor (GIBCO), 8 mM dithiothreithol (GIBCO), 50 units of Superscript RT (GIBCO) and 2 pmol of primer p(dT)15 (Boehringer, Mannheim, Germany); 1 l of cDNA was used in semiquantitative PCRs. Semiquantitative (ratiometric) RT-PCR to detect COX-2 mRNA expression was performed with the use of GAPDH as an internal control. Oligonucleotide primers specific for COX-1 and COX-2 were obtained from Oxford Biomedical Research (Oxford, UK). The COX-1 upstream and downstream primer sequences were 5Ј-CGGGATCCATGAGTCGAAGGAGTCTC-TC-3Ј and 5Ј-GCTCTAGACTCAATGACAATTTTGATGG-3Ј, respectively; the COX-2 upstream and downstream primer sequences were 5Ј-CGGGATCCTGCCAGCTCCACCG-3Ј and 5Ј-GCTCTAGAACAAACTGAGTGAGTCC-3Ј, respectively; GAPDH primers were obtained from Clontech (Palo Alto, CA), and the upstream and downstream primer sequences of GAPDH were 5Ј-TGAAGGTCGGAGTCAACGGATTTGGT-3Ј and 5Ј-CATGTGGGCCATGAGGTCCACCAC-3Ј, respectively. COX-1, COX-2, and GAPDH primers yielded products of 756, 724, and 983 bp, respectively. First, the linear phase of amplification was determined. Therefore, threefold dilutions of cDNA were used with the following PCR conditions: 5 min of denaturation at 95°C, followed by 30 cycles of denaturation at 95°C for 1 min, annealing at 55°C for 1 min, extension at 72°C for 2 min, and a final extension at 72°C for 10 min. The PCR products were loaded on a 1.5% agarose gel containing 0.5 g/ml of ethidium bromide and were subjected to electrophoresis. Optical densities were quantitated by a video densitometer using Molecular Analyst/PC Software version 1.5 (Bio-Rad Laboratories). The log net intensities were plotted against the dilution factors of the cDNA to determine the linear phase of amplification. Dilutions that yielded PCR products lying within the linear range were used for the final PCR reactions, which were performed in duplicate to calculate the ratios between the intensities of COX-1, COX-2, and GAPDH PCR products.
Statistical analysis. Mean values of data obtained from duplicate or triplicate cultures from individual donors were calculated and analyzed using a Wilcoxon's signed-ranks test. Differences were considered significant if P Ͻ 0.05.
RESULTS
Cells started to grow out of the collagenase-stripped bone chips along the bottom of the culture flask after 1-2 wk of culture. The cell layer reached confluency within 2-8 wk, when they were passaged. Treatment of the passaged cells with 10 Ϫ8 M 1,25-dihydroxyvitamin D 3 for 2 days resulted in a 3.3-fold (ranging from 1.8-to 15.4-fold) mean increase in osteocalcin production and a 1.8-fold (ranging from 1.1-to 4.7-fold) mean increase in alkaline phosphatase activity, demonstrating the osteoblastic characteristics of the cell population. Immunostaining for the endothelial cell-specific vWF was performed to preclude the possibility of endothelial cells contaminating the bone cell cultures.
Umbilical cord-derived endothelial cells, which served as a positive control for the immunostaining, were positive for vWF (data not shown). The bone-derived cell cultures, however, did not express vWF, demonstrating that endothelial cells did not contaminate them (data not shown).
Application of PFF for 1 h to the bone-derived cells did not result in visible changes in cell shape or alignment of the cells in the direction of the flow (data not shown). PFF treatment, in either the presence or absence of E 2 , had no effect on the total amount of DNA, demonstrating that no cells were removed by the fluid shear stress (data not shown). Preincubation with E 2 for 2 days had no effect on the total amount of DNA, indicating that E 2 did not affect proliferation.
One hour of PFF treatment in the absence of E 2 increased PGE 2 production in six of seven donors. PGE 2 production remained undetectable in one donor (Fig. 1A) . PFF treatment increased PGI 2 production in six of seven donors. One donor did not respond to PFF treatment (Fig. 1B) . PGF 2␣ production remained undetectable in five of seven donors. Two donors responded to PFF with an increased PGF 2␣ production (Fig. 1C) . Wilcoxon's signed-ranks tests showed that 1 h of PFF treatment resulted in a significant increase (3.0-fold, P Ͻ 0.03) in PGE 2 production expressed as pg/g DNA and a significant increase (2.0-fold, P Ͻ 0.03) in PGI 2 production expressed as picograms per microgram of DNA.
Under stationary conditions, 10 Ϫ11 M E 2 treatment slightly increased PGE 2 production in four of seven donors but decreased PGE 2 production in one donor. The production of PGE 2 remained undetectable in one donor, whereas one donor did not respond to E 2 treatment ( Fig. 2A) . E 2 treatment increased PGI 2 production in five of seven donors but decreased PGI 2 production in two donors (Fig. 2B ). E 2 treatment increased PGF 2␣ production in two of seven donors, whereas PGF 2␣ remained undetectable in five donors (Fig. 2C ). Wilcoxon's signed-ranks tests using all data showed Fig. 1 . Effect of pulsating fluid flow (PFF) on prostaglandin (PG)E 2 , PGI 2 , and PGF 2␣ production by bone cells from individual women. After 1 h of PFF treatment or stationary incubation (control), medium was collected and assayed for PGE 2 (A), PGI 2 , measured as 6-keto-PGF 1␣ , which is the stable metabolite (B), and PGF 2␣ (C), and cells were harvested for DNA isolation. Each point represents the mean of duplicate or triplicate cultures from 1 donor. Lines connect data of parallel cultures of the same donor treated with (F) or without (E) PFF. PG values were normalized for the amount of DNA. Means of pooled data of each group are expressed as horizontal bars. Data of individual donors were used in the Wilcoxon's signed-ranks test. *Significant effect of PFF, P Ͻ 0.03. After 1 h of PFF, PGE 2 , and PGI 2 but not PGF 2␣ levels were increased compared with stationary control levels. http://ajpendo.physiology.org/ that E 2 did not significantly affect PGE 2 , PGI 2 , or PGF 2␣ production under stationary conditions. E 2 treatment enhanced PFF-stimulated PGE 2 production in five of seven donors (Fig. 3A) . E 2 slightly decreased PFF-stimulated PGE 2 production in one donor, whereas PGE 2 production remained undetectable in one donor (Fig. 3A) . E 2 treatment enhanced PFFstimulated PGI 2 production in four of seven donors but inhibited PFF-stimulated PGI 2 production in three donors (Fig. 3B ). E 2 treatment increased PFF-stimulated PGF 2␣ production in two of seven donors (Fig. 3C) . PGF 2␣ production remained undetectable in five donors (Fig. 3C ). Wilcoxon's signed-ranks tests showed that E 2 significantly increased PFF-stimulated PGE 2 (1.9-fold, P Ͻ 0.05), but not PGI 2 or PGF 2␣ production.
One hour of PFF treatment resulted in a 2.9-fold mean increase (P Ͻ 0.05) in COX-2, but not COX-1, mRNA expression (Fig. 4) . E 2 treatment did not significantly change basal COX-1 or COX-2 mRNA expression (Fig. 5) or PFF-dependent COX-1 or COX-2 expression (Fig. 6 ).
DISCUSSION
In a previous study (13) , we showed that human bone cells respond to PFF with increased prostaglandin production and upregulation of COX-2, but not COX-1, mRNA expression. In the present study, we investigated whether estrogen enhancement of adaptive bone formation occurs at the level of mechanosensing by bone cells. Therefore, we pretreated human bone cells for 2 days with E 2 or vehicle and measured their response to PFF. Pretreatment with E 2 enhanced the response to PFF as measured by PGE 2 production, but an effect on PFF-dependent COX-1 or COX-2 mRNA expression could not be demonstrated. Pretreatment with E 2 by itself had no effect on basal PGE 2 production or COX mRNA levels.
As in previous studies with human bone cells (13, 28) , basal prostaglandin production varied considerably between donors. Because we could test only a limited number of donors, we used the Wilcoxon's signed-ranks test, which allowed us to test within- Fig. 2 . Effect of 17␤-estradiol (E 2 ) on PGE 2 , PGI 2 , and PGF 2␣ production by bone cells from individual women. After 2 days of preincubation with 10 Ϫ11 M E 2 or vehicle (control), culture medium was replaced by similar fresh medium. After 1 h of incubation, medium was collected and assayed for PGE 2 (A), PGI 2 (B), and PGF 2␣ (C), and cells were harvested for DNA isolation. Each point represents the mean of duplicate or triplicate cultures from 1 donor. Lines connect data of parallel cultures of the same donor treated with (‚) or without (E) E 2 . PG values were normalized for the amount of DNA. Means of pooled data of each group are expressed as horizontal bars. Data of individual donors were used in the Wilcoxon signed-ranks test. E 2 did not affect PGE 2 , PGI 2 , or PGF 2␣ levels. subject differences rather than the between-subject variation. The reason for the variability in basal prostaglandin production could not be determined in this study and may be related to different lifestyles, medical histories, or genetic backgrounds.
Jagger et al. (12) suggested that estrogen enhances components in the osteogenic response to signals generated by bone cells after mechanical loading, rather then stimulating the stress or strain-sensing system itself. However, the present study suggests that estrogen does indeed act on the sensitivity of the bone cells for mechanical loading and enhances early loadinginduced cell-to-cell signaling by bone cells. A direct comparison between the study by Jagger et al. and the present study is difficult, because different model systems were used. The in vivo model in the study by Jagger et al. is particularly useful to determine relatively late effects on actual bone formation, whereas our in vitro model in the present study is best suitable to investigate relatively early effects at a cellular level. A direct comparison is also difficult because different parameters for the response to mechanical loading were used, namely c-fos and IGF-1 mRNA expression in the study by Jagger et al. and prostaglandin produc- Fig. 4 . Semiquantitative (ratiometric) RT-PCR analysis of the effect of PFF on COX-1 and COX-2 mRNA expression in bone cells from individual women. After 1 h of PFF treatment or stationary incubation (control), total RNA from duplicate or triplicate cultures from 5 (COX-1) or 6 donors (COX-2) was isolated, cDNA was prepared and used in semiquantitative (ratiometric) RT-PCR. A: representative example of semiquantitative RT-PCR. cDNA samples were obtained from 1 donor. According to titration analysis, ϫ10 diluted cDNA was used to obtain COX-2 and GAPDH PCR products lying in the linear range of amplification. COX-1 PCR products were derived from undiluted cDNA. Ten l of PCR product were loaded on the ethidium bromide-stained agarose gel. COX-1, COX-2, and GAPDH primers yielded products of 756, 724, and 983 bp, respectively. COX-1, COX-1 mRNA; COX-2, COX-2 mRNA; GAPDH, GAPDH mRNA; con, control. B: after densitometry, relative levels of COX-1 and COX-2 mRNA were calculated. For each donor, the amount of COX mRNA was normalized against the corresponding level of GAPDH mRNA. Then, control values were set at 1, and experimental values were expressed as treatment over control (T/C) Ϯ SE. Data were used in a Wilcoxon's signed-ranks test. *Significant effect of PFF, P Ͻ 0.05. After 1 h of PFF, COX-2, but not COX-1, mRNA expression was increased compared with stationary control levels. According to titration analysis, ϫ3 diluted cDNA was used to obtain COX-2 PCR products lying in the linear range of amplification. COX-1 PCR products were derived from undiluted cDNA and GAPDH PCR products from ϫ10 (corresponding to COX-1) or ϫ30 (corresponding to COX-2) diluted cDNA. Ten l of PCR product were loaded on the ethidium bromide-stained agarose gel. COX-1, COX-2, and GAPDH primers yielded products of 756, 724, and 983 bp, respectively. E 2 , E 2 treatment. B: relative levels of COX-1 and COX-2 mRNA were calculated as described in Fig. 4 . Data were used in a Wilcoxon's signed-ranks test. E 2 did not affect COX-1 or COX-2 mRNA expression.
tion in the present study. Of these three, prostaglandin production has been tied most directly to adaptive bone formation in response to loading (9) . In the study by Jagger et al. c-fos and IGF-1 mRNA upregulation were not affected by estrogen. The present study shows that E 2 at 10 Ϫ11 M further enhances the effect of mechanical loading on prostaglandin production. Thus the parameters used for measuring bone cell responsiveness to mechanical loading seem to be crucial for the conclusions that are drawn from the results. Finally, Jagger et al. investigated relatively young, predominantly modeling, rat bone. However, because bone loss under estrogen-deficient conditions is associated with increased bone remodeling rather than modeling (27) , we used bone cells that were obtained as outgrowth from predominantly remodeling bone from elderly women. We showed earlier, using finite element analysis, that the remodeling process generates local strain fields within the bone tissue and that active osteoclasts are found on the surface of areas with low strain, whereas active osteoblasts are found on the surface of areas with high strain (25) . We hypothesized that local strain stimulates osteocytes to produce factors such as prostaglandins and nitric oxide that stimulate osteoblast activity and inhibit osteoclast recruitment, respectively (9, 34) . In the present in vitro study, we found that E 2 enhances strain-induced production of PGE 2 , a potent stimulator of bone formation. Therefore, we hypothesize that, in vivo and under estrogen-deficient conditions, osteocytes are less sensitive to local strain during remodeling and produce fewer anabolic products such as PGE 2 , leading to a net bone loss.
In the present study, we found a stimulating effect on PFF-stimulated PGE 2 production already with only a (physiologically) low concentration of 10 Ϫ11 M E 2 . Whether other concentrations of E 2 affect PFF-induced prostaglandin production is unknown, because the limited number of cells obtained from one donor did not allow us to perform dose-response experiments.
Under stationary conditions, 10 Ϫ11 M E 2 did not significantly affect PGE 2 production or COX-1 or COX-2 mRNA expression. Apparently, therefore, E 2 by itself did not modulate COX enzyme activity. The rapid stimulation of PGE 2 release by PFF treatment results most likely from the activity of COX-1, the constitutive form of COX (14, 32) . Cissel et al. (6) demonstrated that E 2 increases bradykinin-stimulated release of arachidonic acid (AA), the substrate for COX. However, basal release of AA was not affected by E 2 (5). Similarly, in the present study, E 2 may have stimulated PFF-induced, but not the basal release of AA, resulting in a higher availability of substrate for the PFF-activated COX-1 enzyme and therefore increased PFFstimulated PGE 2 production. Future studies have to be performed to unravel the exact mechanism of the effect of E 2 on PFF-induced prostaglandin production.
Frost (10) has suggested that estrogen deficiency shifts the "set point" for bone mass adaptation to mechanical loads. One of the factors determining the set point is the sensitivity of bone cells to mechanical stimuli. This hypothesis implies that, if bone cells are more mechanosensitive, lower mechanical forces suffice to maintain skeletal bone mass. Under estrogendeficient conditions, the response of bone cells to mechanical stimulation is reduced, leading to a net negative bone balance. Our in vitro results are in accord with this hypothesis, even if they relate only to the very early steps in the cascade of events leading to bone mass adaptation and maintenance.
In summary, 10 Ϫ11 M E 2 enhanced the fluid shear stress-induced prostaglandin production by cultured bone cells from elderly women. However, 10
Ϫ11 M E 2 Fig. 6 . Semiquantitative (ratiometric) RT-PCR analysis of the effect of PFF in combination with E 2 on COX-1 and COX-2 mRNA expression in bone cells from individual women. Before PFF experiments, cells were preincubated for 2 days in culture medium containing 10 Ϫ11 M E 2 or vehicle. After 1 h of PFF treatment in the presence of E 2 (PFFϩE 2 ) or vehicle (PFF), total RNA from duplicate or triplicate cultures from 4 (COX-1) or 5 donors (COX-2) was isolated, cDNA was prepared and used in semiquantitative RT-PCR. A: representative example of semiquantitative RT-PCR. cDNA samples were obtained from 2 donors. According to titration analysis, ϫ3 diluted cDNA was used to obtain COX-1 and COX-2 PCR products lying in the linear range of amplification. GAPDH PCR products were derived from ϫ10 diluted cDNA. Ten l of PCR product were loaded on the ethidium bromide-stained agarose gel. COX-1, COX-2, and GAPDH primers yielded products of 756, 724, and 983 bp, respectively. PFFϩE 2 , combined PFF and E 2 treatment. B: relative levels of COX-1 and COX-2 mRNA were calculated as described in Fig. 4 . Data were used in a Wilcoxon's signed-ranks test. E 2 did not affect PFF-stimulated COX-2 mRNA expression or PFF-dependent COX-1 mRNA expression.
did not affect basal levels of prostaglandins or COX-1 or COX-2 mRNA expression and did not affect shear stress-induced COX-2 mRNA expression. These results suggest that, in vivo, estrogen may modulate the mechanoresponsiveness of bone tissue by sensitizing the bone cells to mechanical loading through a pathway that is independent of COX expression.
